The Treatment of Small Cell Carcinoma of the Lung with Cyclophosphamide, Vincristine, Methotrexate, and Irradiation

概要

論文の詳細を見る
Thirty patients were treated with COM chemotherapy, receiving 500mg/m2 CPA, 1mg VCR, and 20mg/m2 MTX intravenously on days 1 and 5. The regimens were repeated every 21 days. After two courses of COM, irradiation of the primary lesion, mediastinum and clinically involved cervical nodes was performed in 23 patients. The response rate was 70%(CR 27%, PR 43%) in 30 cases treated with COM alone and 91%(CR 56%, PR 35%) in 23 cases treated with COM + radiotheraphy. Relapse of the primary lesion was recognized in 4 of the responders in the chemotherapy only group and 1 of the responders in the combined group. The median survival was 8 months (range 3-24 months). Severe toxicity of COM was not observed. Combined therapy (COM+R) favorably influences the prognosis of small cell carcinoma of the lung, especially in those patients with limited disease, favorable performance status and continuous chemotheraphy.
特定非営利活動法人日本肺癌学会の論文